| Year |
Citation |
Score |
| 2023 |
Shahani VM, Yue P, Haftchenary S, Zhao W, Lukkarila JL, Zhang X, Ball D, Nona C, Gunning PT, Turkson J. Retraction of "Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies". Acs Medicinal Chemistry Letters. 14: 1482. PMID 37849532 DOI: 10.1021/acsmedchemlett.3c00405 |
0.756 |
|
| 2022 |
Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine. PMID 35229974 DOI: 10.1111/jcmm.17228 |
0.325 |
|
| 2022 |
Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, Olaoye OO, Raouf YS, Sedighi A, Garcha HK, Hassan MM, Gwynne W, Israelian J, Radu TB, Geletu M, ... ... Gunning PT, et al. Discovery of HDAC6-Selective Inhibitor NN-390 with Efficacy in Group 3 Medulloblastoma. Journal of Medicinal Chemistry. 65: 3193-3217. PMID 35119267 DOI: 10.1021/acs.jmedchem.1c01585 |
0.304 |
|
| 2021 |
Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F, Krämer OH. Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers. 13. PMID 34298678 DOI: 10.3390/cancers13143464 |
0.306 |
|
| 2021 |
Geletu M, Adan H, Niit M, Arulanandam R, Carefoot E, Hoskin V, Sina D, Elliott B, Gunning P, Raptis L. Modulation of Akt vs Stat3 activity by the focal adhesion kinase in non-neoplastic mouse fibroblasts. Experimental Cell Research. 112731. PMID 34270980 DOI: 10.1016/j.yexcr.2021.112731 |
0.341 |
|
| 2021 |
Geletu M, Adan H, Niit M, Arulanandam R, Carefoot E, Hoskin V, Sina D, Elliott B, Gunning P, Raptis L. Modulation of Akt vs Stat3 activity by the focal adhesion kinase in non-neoplastic mouse fibroblasts. Experimental Cell Research. 404: 112601. PMID 33957118 DOI: 10.1016/j.yexcr.2021.112601 |
0.341 |
|
| 2021 |
Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, Raouf YS, Manaswiyoungkul P, Erdogan F, Abdeldayem A, Cabral AD, Hassan MM, Toutah K, Shouksmith AE, Gawel JM, ... ... Gunning PT, et al. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype. Journal of Medicinal Chemistry. PMID 33576627 DOI: 10.1021/acs.jmedchem.0c01922 |
0.301 |
|
| 2020 |
Manaswiyoungkul P, de Araujo ED, Gunning PT. Targeting prenylation inhibition through the mevalonate pathway. Rsc Medicinal Chemistry. 11: 51-71. PMID 33479604 DOI: 10.1039/c9md00442d |
0.3 |
|
| 2020 |
de Araujo ED, Keserű GM, Gunning PT, Moriggl R. Targeting STAT3 and STAT5 in Cancer. Cancers. 12. PMID 32707820 DOI: 10.3390/Cancers12082002 |
0.314 |
|
| 2020 |
Hassan MM, Israelian J, Nawar N, Ganda G, Manaswiyoungkul P, Raouf Y, Armstrong D, Sedighi A, Olaoye OO, Erdogan F, Cabral AD, Angeles F, Altintas R, de Araujo ED, Gunning PT. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. Journal of Medicinal Chemistry. PMID 32672458 DOI: 10.1021/Acs.Jmedchem.0C01025 |
0.403 |
|
| 2020 |
Gawel JM, Shouksmith AE, Raouf YS, Nawar N, Toutah K, Bukhari S, Manaswiyoungkul P, Olaoye OO, Israelian J, Radu TB, Cabral AD, Sina D, Sedighi A, de Araujo ED, Gunning PT. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. European Journal of Medicinal Chemistry. 201: 112411. PMID 32615502 DOI: 10.1016/J.Ejmech.2020.112411 |
0.451 |
|
| 2020 |
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, ... ... Gunning PT, et al. STAT5 is Expressed in CD34/CD38 Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers. 12. PMID 32326377 DOI: 10.3390/Cancers12041021 |
0.385 |
|
| 2020 |
Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT. Advances in covalent kinase inhibitors. Chemical Society Reviews. PMID 32227030 DOI: 10.1039/C9Cs00720B |
0.41 |
|
| 2020 |
Geletu M, Hoskin V, Starova B, Niit M, Adan H, Elliott B, Gunning P, Raptis L. Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells. Journal of Visualized Experiments : Jove. PMID 32176212 DOI: 10.3791/60147 |
0.325 |
|
| 2020 |
Manaswiyoungkul P, Erdogan F, Olaoye OO, Cabral AD, de Araujo ED, Gunning PT. Optimization of a high-throughput fluorescence polarization assay for STAT5B DNA binding domain-targeting inhibitors. Journal of Pharmaceutical and Biomedical Analysis. 184: 113182. PMID 32113119 DOI: 10.1016/J.Jpba.2020.113182 |
0.425 |
|
| 2020 |
Shouksmith AE, Gawel JM, Nawar N, Sina D, Raouf YS, Bukhari S, He L, Johns AE, Manaswiyoungkul P, Olaoye OO, Cabral AD, Sedighi A, de Araujo ED, Gunning PT. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. Acs Medicinal Chemistry Letters. 11: 56-64. PMID 31938464 DOI: 10.1021/Acsmedchemlett.9B00471 |
0.381 |
|
| 2020 |
Orlova A, Kosack L, Popa AM, Viczenczova C, Lercher A, Araujo EDd, Gunning P, Moriggl R, Bergthaler A. Abstract 5636: Restoration of tumor immunosurveillance in tasmanian devil facial tumor disease Immunology. 80: 5636-5636. DOI: 10.1158/1538-7445.Am2020-5636 |
0.452 |
|
| 2020 |
Meneksedag-Erol D, de Araujo ED, Erdogan F, Seo H, Dhe-Paganon S, Gunning PT, Rauscher S. Cancer Activating Mutations in STAT5B: Elucidating the Impact on Protein Structure and Dynamics using Atomistic Molecular Simulations Biophysical Journal. 118: 504a. DOI: 10.1016/J.Bpj.2019.11.2779 |
0.305 |
|
| 2019 |
Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, Gunning PT, Keserű GM, Moriggl R. Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers. 11. PMID 31817042 DOI: 10.3390/Cancers11121930 |
0.468 |
|
| 2019 |
de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. Cancers. 11. PMID 31717342 DOI: 10.3390/Cancers11111757 |
0.38 |
|
| 2019 |
Niit M, Geletu M, Taha Z, Arulanandam R, Cass J, Hoskin V, Elliott B, Gunning P, Raptis L. Regulation of Differentiation of HC11 Mouse Breast Epithelial Cells by the Signal Transducer and Activator of Transcription-3. Anticancer Research. 39: 2749-2756. PMID 31177110 DOI: 10.21873/Anticanres.13401 |
0.32 |
|
| 2019 |
de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, ... ... Gunning PT, et al. Structural and functional consequences of the STAT5B driver mutation. Nature Communications. 10: 2517. PMID 31175292 DOI: 10.1038/S41467-019-10422-7 |
0.342 |
|
| 2019 |
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, ... ... Gunning PT, et al. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. PMID 31123029 DOI: 10.3324/Haematol.2019.216986 |
0.343 |
|
| 2019 |
Geletu M, Taha Z, Arulanandam R, Mohan R, Assi HH, Castro MG, Nabi IR, Gunning PT, Raptis L. Effect of Caveolin-1 upon Stat3-ptyr705 levels in breast and lung carcinoma cells. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. PMID 30986357 DOI: 10.1139/Bcb-2018-0367 |
0.356 |
|
| 2019 |
Linher-Melville K, Sharma M, Nakhla P, Kum E, Ungard R, Park J, Rosa D, Gunning P, Singh G. Inhibiting STAT3 in a murine model of human breast cancer-induced bone pain delays the onset of nociception. Molecular Pain. 15: 1744806918823477. PMID 30799695 DOI: 10.1177/1744806918823477 |
0.336 |
|
| 2019 |
Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf Y, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, ... ... Gunning PT, et al. Identification and Characterization of AES-135, a Hydroxamic Acid-based HDAC Inhibitor that Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry. PMID 30776234 DOI: 10.1021/Acs.Jmedchem.8B01957 |
0.367 |
|
| 2019 |
Geletu M, Taha Z, Gunning PT, Raptis L. PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication. Cancers. 11. PMID 30717267 DOI: 10.3390/Cancers11020167 |
0.419 |
|
| 2019 |
Kosack L, Wingelhofer B, Popa A, Orlova A, Agerer B, Vilagos B, Majek P, Parapatics K, Lercher A, Ringler A, Klughammer J, Smyth M, Khamina K, Baazim H, de Araujo ED, ... ... Gunning PT, et al. The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell. 35: 125-139.e9. PMID 30645971 DOI: 10.1016/J.Ccell.2018.11.018 |
0.417 |
|
| 2018 |
de Araujo ED, Manaswiyoungkul P, Erdogan F, Qadree AK, Sina D, Tin G, Toutah K, Yuen K, Gunning PT. A functional in vitro assay for screening inhibitors of STAT5B phosphorylation. Journal of Pharmaceutical and Biomedical Analysis. 162: 60-65. PMID 30223143 DOI: 10.1016/J.Jpba.2018.08.036 |
0.491 |
|
| 2018 |
Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. PMID 29728695 DOI: 10.1038/S41375-018-0117-X |
0.44 |
|
| 2018 |
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, ... ... Gunning PT, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. PMID 29472718 DOI: 10.1038/S41375-017-0005-9 |
0.517 |
|
| 2018 |
Geletu M, Mohan R, Arulanandam R, Berger-Becvar A, Nabi IR, Gunning PT, Raptis L. Reciprocal regulation of the Cadherin-11/Stat3 axis by caveolin-1 in mouse fibroblasts and lung carcinoma cells. Biochimica Et Biophysica Acta. PMID 29458077 DOI: 10.1016/J.Bbamcr.2018.02.004 |
0.471 |
|
| 2017 |
Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opinion On Therapeutic Targets. PMID 29148847 DOI: 10.1080/14728222.2018.1406924 |
0.343 |
|
| 2017 |
Niit M, Arulanandam R, Cass J, Geletu M, Hoskin V, Côté G, Gunning P, Elliott B, Raptis L. Regulation of HC11 mouse breast epithelial cell differentiation by the E-cadherin/Rac axis. Experimental Cell Research. PMID 29031557 DOI: 10.1016/J.Yexcr.2017.10.008 |
0.345 |
|
| 2017 |
Cabral AD, Murcar-Evans BI, Toutah K, Bancerz M, Rosa D, Yuen K, Radu TB, Ali M, Penkul A, Kraskouskaya D, Gunning PT. Structure-activity relationship study of ProxyPhos chemosensors for the detection of proximal phosphorylation and other phosphate species. The Analyst. PMID 28930308 DOI: 10.1039/C7An00722A |
0.336 |
|
| 2017 |
de Araujo ED, Manaswiyoungkul P, Israelian J, Park J, Yuen K, Farhangi S, Berger-Becvar A, Abu-Jazar L, Gunning PT. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains. Journal of Pharmaceutical and Biomedical Analysis. 143: 159-167. PMID 28600954 DOI: 10.1016/J.Jpba.2017.04.052 |
0.484 |
|
| 2017 |
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. PMID 28596283 DOI: 10.3324/Haematol.2016.163436 |
0.449 |
|
| 2017 |
Kraskouskaya D, Cabral AD, Fong R, Bancerz M, Toutah K, Rosa D, Gardiner JE, de Araujo ED, Duodu E, Armstrong D, Fekl U, Gunning PT. Characterization and application studies of ProxyPhos, a chemosensor for the detection of proximally phosphorylated peptides and proteins in aqueous solutions. The Analyst. PMID 28574079 DOI: 10.1039/C6An02537D |
0.347 |
|
| 2017 |
Paiva SL, da Silva SR, de Araujo ED, Gunning PT. Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site. Journal of Medicinal Chemistry. PMID 28076680 DOI: 10.1021/Acs.Jmedchem.6B01346 |
0.367 |
|
| 2017 |
Linher-Melville K, Nashed M, Ungard R, Haftchenary S, Gunning P, Singh G. Abstract P3-03-13: Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxyten species/SUMOylation pathway and its effects on xCT expression and system xc-activity Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-13 |
0.392 |
|
| 2017 |
Wingelhofer B, Maurer B, Heyes EC, Freund P, Cumaraswamy AA, Park J, Kubicek S, Valent P, Gunning PT, Moriggl R. Abstract 1184: Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases Cancer Research. 77: 1184-1184. DOI: 10.1158/1538-7445.Am2017-1184 |
0.538 |
|
| 2016 |
Garg N, Bakhshinyan D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, Manoranjan B, Hallett R, McFarlane N, Delaney KH, Kwiecien JM, Arpin CC, Lai PS, Gómez-Biagi RF, Ali AM, ... ... Gunning PT, et al. CD133(+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. PMID 27775079 DOI: 10.1038/Onc.2016.235 |
0.407 |
|
| 2016 |
de Araujo ED, Geletu M, Gunning PT. Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli. Protein Expression and Purification. PMID 27590918 DOI: 10.1016/J.Pep.2016.08.017 |
0.373 |
|
| 2016 |
Linher-Melville K, Nashed MG, Ungard RG, Haftchenary S, Rosa DA, Gunning PT, Singh G. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity. Plos One. 11: e0161202. PMID 27513743 DOI: 10.1371/Journal.Pone.0161202 |
0.445 |
|
| 2016 |
Wilson AJ, Gunning PT. Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 2). Chemmedchem. PMID 27061459 DOI: 10.1002/Cmdc.201600158 |
0.305 |
|
| 2016 |
Ali AM, Gómez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT. Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. Chemmedchem. PMID 27028877 DOI: 10.1002/Cmdc.201600021 |
0.478 |
|
| 2016 |
Belton A, Xian L, Huso T, Koo M, Luo LZ, Turkson J, Page BD, Gunning PT, Liu G, Huso DL, Resar LM. STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway. Leukemia & Lymphoma. 1-4. PMID 26952843 DOI: 10.3109/10428194.2016.1153089 |
0.658 |
|
| 2016 |
Ball DP, Lewis AM, Williams D, Resetca D, Wilson DJ, Gunning PT. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent. Oncotarget. PMID 26942696 DOI: 10.18632/Oncotarget.7838 |
0.409 |
|
| 2016 |
Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gomez-Biagi RF, Ali AM, Rana R, ... ... Gunning PT, et al. Applying Small Molecule Signal Transducer and Activator of Trancription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Molecular Cancer Therapeutics. PMID 26873728 DOI: 10.1158/1535-7163.Mct-15-0003 |
0.711 |
|
| 2016 |
Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, et al. STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discovery. 6: 414-29. PMID 26873347 DOI: 10.1158/2159-8290.Cd-15-0732 |
0.374 |
|
| 2016 |
Duodu E, Kraskouskaya D, Gómez-Biagi RF, Gunning PT. A tool for the selective sequestration of ATP and PPi to aid in-solution phosphopeptide detection assays. The Analyst. 141: 820-2. PMID 26643551 DOI: 10.1039/C5An01414J |
0.302 |
|
| 2016 |
Gleixner KV, Schneeweiss MA, Herrmann H, Blatt K, Berger D, Eisenwort G, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Gunning PT, Maeda H, Moriggl R, Deininger MW, et al. Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml Blood. 128: 4241-4241. DOI: 10.1182/Blood.V128.22.4241.4241 |
0.356 |
|
| 2016 |
Fishel ML, Grimard ML, Kelley MR, Rosa DA, Shouksmith A, Tin G, Park J, Gunning PT. Abstract 1246: Development of STAT3 dual-targeting strategies for the treatment of pancreatic cancer Cancer Research. 76: 1246-1246. DOI: 10.1158/1538-7445.Am2016-1246 |
0.516 |
|
| 2016 |
Ali AM, Gómez-Biagi RF, Rosa DA, Lai P, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT. Inside Cover: Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities (ChemMedChem 8/2016) Chemmedchem. 11: 731-731. DOI: 10.1002/Cmdc.201600185 |
0.341 |
|
| 2015 |
da Silva SR, Paiva SL, Bancerz M, Geletu M, Lewis AM, Chen J, Cai Y, Lukkarila JL, Li H, Gunning PT. A selective inhibitor of the UFM1-activating enzyme, UBA5. Bioorganic & Medicinal Chemistry Letters. PMID 27520940 DOI: 10.1016/J.Bmcl.2015.10.015 |
0.45 |
|
| 2015 |
Haftchenary S, Jouk AO, Aubry I, Lewis AM, Landry M, Ball DP, Shouksmith AE, Collins CV, Tremblay ML, Gunning PT. Identification of Bidentate Salicylic Acid Inhibitors of PTP1B. Acs Medicinal Chemistry Letters. 6: 982-6. PMID 26396684 DOI: 10.1021/Acsmedchemlett.5B00171 |
0.41 |
|
| 2015 |
Lai PS, Rosa DA, Magdy Ali A, Gómez-Biagi RF, Ball DP, Shouksmith AE, Gunning PT. A STAT inhibitor patent review: progress since 2011. Expert Opinion On Therapeutic Patents. 1-25. PMID 26394986 DOI: 10.1517/13543776.2015.1086749 |
0.434 |
|
| 2015 |
Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, ... ... Gunning PT, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. PMID 26314961 DOI: 10.18632/Oncotarget.4742 |
0.651 |
|
| 2015 |
Linher-Melville K, Haftchenary S, Gunning P, Singh G. Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells. Molecular and Cellular Biochemistry. 405: 205-21. PMID 25896132 DOI: 10.1007/S11010-015-2412-4 |
0.461 |
|
| 2015 |
Arabzadeh A, Dupaul-Chicoine J, Breton V, Haftchenary S, Yumeen S, Turbide C, Saleh M, McGregor K, Greenwood CM, Akavia UD, Blumberg RS, Gunning PT, Beauchemin N. Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells. Gut. PMID 25666195 DOI: 10.1136/Gutjnl-2014-308781 |
0.313 |
|
| 2015 |
Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, ... ... Gunning PT, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 29: 586-97. PMID 25134459 DOI: 10.1038/Leu.2014.245 |
0.688 |
|
| 2015 |
Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, ... ... Gunning PT, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation Oncotarget. 6: 27461-27477. DOI: 10.18632/oncotarget.4742 |
0.573 |
|
| 2015 |
Linher-Melville K, Fazzari J, Gunning P, Singh G. Abstract P5-07-05: Regulation of system Xc- by signal transducer and activator of transcription 3 and 5 in human breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-07-05 |
0.476 |
|
| 2015 |
Paiva S, Silva Sd, Bancerz M, Geletu M, Lewis AM, Chen J, Cai Y, Lukkarila JL, Li H, Gunning PT. Abstract LB-C19: The investigation of structural determinants that mediate selective inhibition of UBA5, the UFM1 activating enzyme Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C19 |
0.459 |
|
| 2015 |
Silva SRd, Geletu M, Javed F, Paiva S, Lewis AM, Li H, Gunning PT. Abstract LB-A13: Cellular characterization of the selective inhibition of UBA5 by organometallic, adenosine-based inhibitors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-A13 |
0.405 |
|
| 2015 |
Zeidan N, Su H, Aitken M, Gunning PT, Kerman K. Magnetic bead-based electrochemical detection of interaction between epigallocatechin-3-gallate and STAT proteins Analytical Methods. 7: 3566-3569. DOI: 10.1039/C5Ay00169B |
0.382 |
|
| 2015 |
Wingelhofer B, Heyes EC, Lewis AM, Cumaraswamy AA, Sadovnik I, Valent P, Kubicek S, Gunning PT, Moriggl R. ID: 66 Cytokine. 76: 77. DOI: 10.1016/J.Cyto.2015.08.096 |
0.509 |
|
| 2014 |
Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leukemia Supplements. 3: S5-6. PMID 27175272 DOI: 10.1038/leusup.2014.3 |
0.571 |
|
| 2014 |
Cumaraswamy AA, Lewis AM, Geletu M, Todic A, Diaz DB, Cheng XR, Brown CE, Laister RC, Muench D, Kerman K, Grimes HL, Minden MD, Gunning PT. Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. Acs Medicinal Chemistry Letters. 5: 1202-1206. PMID 25419444 DOI: 10.1021/Ml500165R |
0.52 |
|
| 2014 |
Resetca D, Haftchenary S, Gunning PT, Wilson DJ. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization. The Journal of Biological Chemistry. 289: 32538-47. PMID 25288792 DOI: 10.1074/Jbc.M114.595454 |
0.467 |
|
| 2014 |
Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, ... ... Gunning PT, et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Science Signaling. 7: ra38. PMID 24757178 DOI: 10.1126/Scisignal.2004839 |
0.703 |
|
| 2014 |
Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. Plos One. 9: e93530. PMID 24691136 DOI: 10.1182/Blood.V122.21.2527.2527 |
0.375 |
|
| 2014 |
Martic S, Rains MK, Haftchenary S, Shahani VM, Kraskouskaya D, Ball DP, Gunning PT, Kraatz HB. Electrochemical detection of the Fc-STAT3 phosphorylation and STAT3-Fc-STAT3 dimerization and inhibition. Molecular Biosystems. 10: 576-80. PMID 24402062 DOI: 10.1039/C3Mb70493A |
0.797 |
|
| 2014 |
Kraskouskaya D, Bancerz M, Soor HS, Gardiner JE, Gunning PT. An excimer-based, turn-on fluorescent sensor for the selective detection of diphosphorylated proteins in aqueous solution and polyacrylamide gels. Journal of the American Chemical Society. 136: 1234-7. PMID 24387313 DOI: 10.1021/Ja411492K |
0.328 |
|
| 2014 |
Heaton WL, Eiring AM, Vellore NA, Resetca D, Haftchenary S, Rosa D, Ali AM, Senina AV, Pomicter AD, Page BD, Kraft IL, Reynolds KR, Wilson DJ, Baron R, O'Hare T, ... Gunning PT, et al. Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders Blood. 124: 4816-4816. DOI: 10.1182/Blood.V124.21.4816.4816 |
0.702 |
|
| 2014 |
Paiva S, da Silva S, Bancerz M, Quereshi H, Xu G, Schimmer A, Gunning P. 286 Potent and selective non-sulfamate-containing small molecule inhibitors of the ubiquitin activating enzyme European Journal of Cancer. 50: 95. DOI: 10.1016/S0959-8049(14)70412-5 |
0.401 |
|
| 2014 |
da Silva S, Paiva S, Bancerz M, Geletu M, Lewis A, Chen J, Cai Y, Li H, Gunning P. 283 The development of the first selective inhibitors of the UBA5 enzyme to probe for E1 activity in diseased cells European Journal of Cancer. 50: 94. DOI: 10.1016/S0959-8049(14)70409-5 |
0.34 |
|
| 2013 |
Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, ... Gunning PT, et al. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. Acs Medicinal Chemistry Letters. 4: 1102-7. PMID 24900612 DOI: 10.1021/ml4003138 |
0.822 |
|
| 2013 |
Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. Journal of Medicinal Chemistry. 56: 7190-200. PMID 23968501 DOI: 10.1021/Jm3017255 |
0.727 |
|
| 2013 |
Shahani VM, Ball DP, Ramos AV, Li Z, Spagnuolo PA, Haftchenary S, Schimmer AD, Trudel S, Gunning PT. A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. Bioorganic & Medicinal Chemistry. 21: 5618-28. PMID 23810672 DOI: 10.1016/J.Bmc.2013.04.080 |
0.785 |
|
| 2013 |
Avadisian M, Gunning PT. Extolling the benefits of molecular therapeutic lipidation. Molecular Biosystems. 9: 2179-88. PMID 23771042 DOI: 10.1039/C3Mb70147F |
0.381 |
|
| 2013 |
Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BD, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. Embo Molecular Medicine. 5: 572-90. PMID 23460527 DOI: 10.1002/Emmm.201201876 |
0.625 |
|
| 2013 |
Kraskouskaya D, Duodu E, Arpin CC, Gunning PT. Progress towards the development of SH2 domain inhibitors. Chemical Society Reviews. 42: 3337-70. PMID 23396540 DOI: 10.1039/C3Cs35449K |
0.413 |
|
| 2013 |
da Silva SR, Paiva SL, Lukkarila JL, Gunning PT. Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes. Journal of Medicinal Chemistry. 56: 2165-77. PMID 23360215 DOI: 10.1021/Jm301420B |
0.415 |
|
| 2013 |
Xu W, Lukkarila JL, da Silva SR, Paiva SL, Gunning PT, Schimmer AD. Targeting the ubiquitin E1 as a novel anti-cancer strategy. Current Pharmaceutical Design. 19: 3201-9. PMID 23151135 DOI: 10.2174/1381612811319180004 |
0.441 |
|
| 2013 |
Eiring AM, Kraft IL, Page BD, Zhang TY, Khorashad JS, Vellore NA, Reynolds KR, Pomicter AD, Senina AV, Zabriskie MS, Ahmad S, Mason CC, Moriggl R, Baron R, O'Hare T, ... Gunning PT, et al. BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia Blood. 122: 854-854. DOI: 10.1182/Blood.V122.21.854.854 |
0.679 |
|
| 2013 |
Croucher DC, Li Z, Page BD, Wei EN, Gunning PT, Trudel S. A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma Blood. 122: 4441-4441. DOI: 10.1182/Blood.V122.21.4441.4441 |
0.731 |
|
| 2013 |
Yue P, Haftchenary S, Gunning PT, Turkson J. Abstract 3253: A novel small-molecule inhibitor of Stat3 induces antitumor cell effects in human glioma and breast cancer cells. Cancer Research. 73: 3253-3253. DOI: 10.1158/1538-7445.Am2013-3253 |
0.504 |
|
| 2013 |
Li ZH, Haftchenary S, Croucher D, Gunning PT, Trudel S. Abstract C246: SH-4-54, a novel small-molecule inhibitor of STAT3, demonstrates significant anti-tumor activity against multiple myeloma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C246 |
0.555 |
|
| 2013 |
Croucher DC, Li ZH, Page BD, Wei E, Gunning PT, Trudel S. Abstract A260: BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A260 |
0.737 |
|
| 2013 |
Haftchenary S, Ball DP, Aubry I, Landry M, Shahani VM, Fletcher S, Page BDG, Jouk AO, Tremblay ML, Gunning PT. Identification of a potent salicylic acid-based inhibitor of tyrosine phosphatase PTP1B Medchemcomm. 4: 987-992. DOI: 10.1039/C3Md00011G |
0.772 |
|
| 2013 |
Kraskouskaya D, Drewry JA, Duodu E, Burger S, Eaton J, Cisneros GA, Gunning PT. Exploring the structural determinants of selective phosphopeptide recognition using bivalent metal-coordination complexes Medchemcomm. 4: 289-292. DOI: 10.1039/C2Md20342A |
0.769 |
|
| 2012 |
Burger SK, Lacasse M, Verstraelen T, Drewry J, Gunning P, Ayers PW. Automated Parametrization of AMBER Force Field Terms from Vibrational Analysis with a Focus on Functionalizing Dinuclear Zinc(II) Scaffolds. Journal of Chemical Theory and Computation. 8: 554-62. PMID 26596604 DOI: 10.1021/Ct2007742 |
0.748 |
|
| 2012 |
Cumaraswamy AA, Gunning PT. Progress towards direct inhibitors of Stat5 protein. Hormone Molecular Biology and Clinical Investigation. 10: 281-6. PMID 25436685 DOI: 10.1515/Hmbci-2012-0009 |
0.472 |
|
| 2012 |
Drewry JA, Duodu E, Mazouchi A, Spagnuolo P, Burger S, Gradinaru CC, Ayers P, Schimmer AD, Gunning PT. Phosphopeptide selective coordination complexes as promising SRC homology 2 domain mimetics. Inorganic Chemistry. 51: 8284-91. PMID 22784241 DOI: 10.1021/Ic3008393 |
0.805 |
|
| 2012 |
Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT, Turkson J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America. 109: 9623-8. PMID 22623533 DOI: 10.1073/Pnas.1121606109 |
0.713 |
|
| 2012 |
Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, Yue P, Turkson J, Minden MD, Gunning PT. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. Journal of Medicinal Chemistry. 55: 1047-55. PMID 22148584 DOI: 10.1021/Jm200720N |
0.751 |
|
| 2012 |
Mitra RN, Doshi M, Zhang X, Tyus JC, Bengtsson N, Fletcher S, Page BD, Turkson J, Gesquiere AJ, Gunning PT, Walter GA, Santra S. An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials. 33: 1500-8. PMID 22078810 DOI: 10.1016/J.Biomaterials.2011.10.068 |
0.61 |
|
| 2012 |
Jimenez-Zepeda VH, Page BD, Hua LZ, Wei E, Bergsagel L, Gunning PT, Trudel S. BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma Blood. 120: 576-576. DOI: 10.1182/Blood.V120.21.576.576 |
0.731 |
|
| 2012 |
Eiring AM, Kraft IL, Page BD, Anderson DJ, Gu Z, Khorashad JS, Pomicter AD, Reynolds KR, Zabriskie MS, Moriggl R, Gunning PT, O'Hare T, Deininger MW. STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML) Blood. 120: 31-31. DOI: 10.1182/Blood.V120.21.31.31 |
0.689 |
|
| 2012 |
Kraft IL, Eiring AM, Page BD, Mason CC, Gu Z, Khorashad JS, Anderson DJ, Pomicter AD, Reynolds KR, Estrada J, Zabriskie MS, Gunning PT, O'Hare T, Deininger MW. Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia. Blood. 120: 2445-2445. DOI: 10.1182/Blood.V120.21.2445.2445 |
0.708 |
|
| 2012 |
Yue P, Zhang X, Page BD, Zhao W, Paladino D, Gunning PT, Turkson J. Abstract LB-354: A novel orally-bioavailable small-molecule inhibitor of Stat3 regresses human breast and lung cancer xenografts Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-354 |
0.724 |
|
| 2012 |
Drewry JA, Burger S, Mazouchi A, Duodu E, Ayers P, Gradinaru CC, Gunning PT. Src homology 2 domain proteomimetics: Developing phosphopeptide selective receptors Medchemcomm. 3: 763-770. DOI: 10.1039/C2Md20052J |
0.79 |
|
| 2012 |
Cumaraswamy AA, Todic A, Resetca D, Minden MD, Gunning PT. Inhibitors of Stat5 protein signalling Medchemcomm. 3: 22-27. DOI: 10.1039/C1Md00175B |
0.427 |
|
| 2011 |
Lukkarila JL, da Silva SR, Ali M, Shahani VM, Xu GW, Berman J, Roughton A, Dhe-Paganon S, Schimmer AD, Gunning PT. Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity. Acs Medicinal Chemistry Letters. 2: 577-82. PMID 24900352 DOI: 10.1021/Ml2000615 |
0.769 |
|
| 2011 |
Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorganic & Medicinal Chemistry Letters. 21: 5605-9. PMID 21788134 DOI: 10.1016/J.Bmcl.2011.06.056 |
0.757 |
|
| 2011 |
Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. Chemmedchem. 6: 1459-70. PMID 21618433 DOI: 10.1002/Cmdc.201100194 |
0.734 |
|
| 2011 |
Shahani VM, Yue P, Haftchenary S, Zhao W, Lukkarila JL, Zhang X, Ball D, Nona C, Gunning PT, Turkson J. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. Acs Medicinal Chemistry Letters. 2: 79-84. PMID 21243039 DOI: 10.1021/Ml100224D |
0.813 |
|
| 2011 |
Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, Zhang X, Sun H, Zhao W, Schimmer AD, Turkson J, Gunning PT. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorganic & Medicinal Chemistry. 19: 1823-38. PMID 21216604 DOI: 10.1016/J.Bmc.2010.12.010 |
0.814 |
|
| 2011 |
Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 21: 65-83. PMID 21114420 DOI: 10.1517/13543776.2011.539205 |
0.713 |
|
| 2011 |
Haftchenary S, Avadisian M, Gunning PT. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anti-Cancer Drugs. 22: 115-27. PMID 21063201 DOI: 10.1097/Cad.0B013E328341185B |
0.485 |
|
| 2011 |
Croucher DC, Jimenez-Zepeda VH, Li ZH, Wei E, Page BD, Turkson J, Gunning PT, Trudel S. The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia Blood. 118: 5101-5101. DOI: 10.1182/Blood.V118.21.5101.5101 |
0.729 |
|
| 2011 |
Zhang X, Page BDG, Yue P, Fletcher S, Zhao W, Gunning P, Turkson J. Abstract 4512: A novel orally-bioavailable salicylic acid-based small molecular Stat3 inhibitor suppress growth of human breast tumor xenografts Cancer Research. 71: 4512-4512. DOI: 10.1158/1538-7445.Am2011-4512 |
0.531 |
|
| 2011 |
Cumaraswamy AA, Gunning PT. Abstract B224: Structure-based drug design of signal transducers and activator of transcription 5 inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B224 |
0.567 |
|
| 2011 |
Avadisian M, Fletcher S, Liu B, Zhao W, Yue P, Turkson J, Gradinaru C, Gunning P. Abstract B220: Artificially inducing protein-membrane anchorage: Introducing a new therapeutic modality. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B220 |
0.43 |
|
| 2011 |
Croucher DC, Jimenez-Zepeda VH, Page BD, Li ZH, Wei E, Turkson J, Gunning PT, Trudel S. Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A201 |
0.731 |
|
| 2011 |
Page BDG, Zhang X, Atkinson J, Li ZH, Schimmer AD, Trudel S, Turkson J, Gunning PT. Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A125 |
0.506 |
|
| 2011 |
Page BDG, Atkinson J, Wong YL, Haftchenary S, Spagnuolo PA, Kraft IL, O'Hare T, Turkson J, Deininger MW, Schimmer AD, Gunning PT. Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A121 |
0.536 |
|
| 2011 |
Drewry JA, Gunning PT. Recent advances in biosensory and medicinal therapeutic applications of zinc(II) and copper(II) coordination complexes Coordination Chemistry Reviews. 255: 459-472. DOI: 10.1016/J.Ccr.2010.10.018 |
0.768 |
|
| 2010 |
Drewry JA, Fletcher S, Yue P, Marushchak D, Zhao W, Sharmeen S, Zhang X, Schimmer AD, Gradinaru C, Turkson J, Gunning PT. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chemical Communications (Cambridge, England). 46: 892-4. PMID 20107641 DOI: 10.1039/B919608K |
0.791 |
|
| 2010 |
Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochemical Pharmacology. 79: 1398-409. PMID 20067773 DOI: 10.1016/J.Bcp.2010.01.001 |
0.476 |
|
| 2010 |
Jimenez-Zepeda VH, Li ZH, Page BD, Zeng S, Wei E, Leung-Hagesteijn C, Turkson J, Gunning PT, Trudel S. Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity Blood. 116: 138-138. DOI: 10.1182/Blood.V116.21.138.138 |
0.725 |
|
| 2010 |
Fletcher S, Page BDG, Yue P, Zhang X, Sharmeen S, Schimmer AD, Turkson J, Gunning PT. Abstract 3684: Developing STAT3 protein inhibitors as adjuvant therapeutics: Promising synergistic effects in human cancers Cancer Research. 70: 3684-3684. DOI: 10.1158/1538-7445.Am10-3684 |
0.42 |
|
| 2010 |
Fletcher S, Shahani VM, Lough AJ, Gunning PT. Concise access to N9-mono-, N2-mono- and N2,N9-di-substituted guanines via efficient Mitsunobu reactions Tetrahedron. 66: 4621-4632. DOI: 10.1016/J.Tet.2010.03.118 |
0.712 |
|
| 2009 |
Drewry JA, Fletcher S, Hassan H, Gunning PT. Novel asymmetrically functionalized bis-dipicolylamine metal complexes: peripheral decoration of a potent anion recognition scaffold. Organic & Biomolecular Chemistry. 7: 5074-7. PMID 20024100 DOI: 10.1039/B917692F |
0.771 |
|
| 2009 |
Fletcher S, Drewry JA, Shahani VM, Page BD, Gunning PT. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 87: 825-33. PMID 19935868 DOI: 10.1139/o09-044 |
0.801 |
|
| 2009 |
Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem : a European Journal of Chemical Biology. 10: 1959-64. PMID 19644994 DOI: 10.1002/Cbic.200900172 |
0.832 |
|
| 2009 |
Page BDG, Fletcher S, Schimmer A, Turkson J, Gunning PT. Abstract C40: Salicylic acid‐based small molecule inhibitors of Stat3 show potent and selective activity in a variety of human cancer cell lines Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C40 |
0.536 |
|
| 2009 |
Siddiquee KAZ, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects (ACS Chemical Biology (2007) 2, (787-798)) Acs Chemical Biology. 4: 309. DOI: 10.1021/Cb9000684 |
0.396 |
|
| 2009 |
Fletcher S, Shahani VM, Gunning PT. Facile and efficient access to 2,6,9-tri-substituted purines through sequential N9, N2 Mitsunobu reactions Tetrahedron Letters. 50: 4258-4261. DOI: 10.1016/J.Tetlet.2009.04.137 |
0.707 |
|
| 2009 |
Fletcher S, Singh J, Zhang X, Yue P, Page BDG, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Inside Cover: Disruption of Transcriptionally Active Stat3 Dimers with Non-phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities (ChemBioChem 12/2009) Chembiochem. 10: 1906-1906. DOI: 10.1002/Cbic.200990048 |
0.779 |
|
| 2008 |
Gunning PT, Glenn MP, Siddiquee KA, Katt WP, Masson E, Sebti SM, Turkson J, Hamilton AD. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem : a European Journal of Chemical Biology. 9: 2800-3. PMID 19006150 DOI: 10.1002/Cbic.200800291 |
0.46 |
|
| 2008 |
Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. Chemmedchem. 3: 1159-68. PMID 18683176 DOI: 10.1002/Cmdc.200800123 |
0.494 |
|
| 2008 |
Fletcher S, Turkson J, Gunning PT. Cover Picture: Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein (ChemMedChem 8/2008) Chemmedchem. 3: 1145-1145. DOI: 10.1002/Cmdc.200890030 |
0.442 |
|
| 2007 |
Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. Acs Chemical Biology. 2: 787-98. PMID 18154266 DOI: 10.1021/Cb7001973 |
0.448 |
|
| 2007 |
Gunning PT, Katt WP, Glenn M, Siddiquee K, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorganic & Medicinal Chemistry Letters. 17: 1875-8. PMID 17336521 DOI: 10.1016/J.Bmcl.2007.01.077 |
0.489 |
|
| 2007 |
Gunning PT, Katt WP, Glenn M, Siddiquee K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Corrigendum to "Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains" [Bioorg. Med. Chem. Lett. 17 (2007) 1875-1878] (DOI:10.1016/j.bmcl.2007.01.077) Bioorganic and Medicinal Chemistry Letters. 17: 2949. DOI: 10.1016/J.Bmcl.2007.03.063 |
0.407 |
|
| 2006 |
Siddiquee S, Glenn M, Gunning P, Guida W, Lawrence N, McLaughlin M, Sebti S, Jove R, Hamilton A, Turkson J. 547 POSTER Novei small-molecule inhibitors of STAT3 that selectively induce antitumor cell activity European Journal of Cancer Supplements. 4: 166. DOI: 10.1016/S1359-6349(06)70552-3 |
0.346 |
|
| Show low-probability matches. |